Bayer Intellectual Property Gmbh

Bayer IP Gmbh

Bayer Schering Pharma Ag

Thomas Langguth

Stefan Bracht

Michael Dittgen

Dirk Schenk

Ildiko Terebesi

Jan-Peter Ingwersen

Petra Huber

Hubert Kaffl

Stephan Mletzko

Manfred Suesse

Jochen Schumacher

Jochen Schuhmacher

Drik Schenk

The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV-radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.

UV stable transdermal therapeutic plaster with a UV absorbing self-adhesive layer separated from the drug matrix

The invention relates to pharmaceutical formulations, in particular to transdermal therapeutic systems, which are characterized in that little or no active ingredient crystallizes out at the interface between the removable protective film (release liner) and the active-ingredient-containing matrix.

Transdermal therapeutic system with crystallization-inhibiting protective film (release liner)

The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.

Transdermal delivery of hormones with low concentration of penetration enhancers

The UV-stable solid transdermal therapeutic system (TTS) with UV absorber for photosensitive active pharmaceutical ingredients has a backing layer (), at least one active ingredient-containing matrix (), and a detachable protective film (). Optionally an adhesive layer () and a separating layer () are introduced between the backing layer () and the at least one active ingredient-containing matrix (). At least one hydroxyphenyltriazine compound acting as UV absorber is embedded in the backing layer (), in the active ingredient-containing matrix (), or in the adhesive layer (). The TTS according to the invention achieves high stability at low concentrations of UV absorber, preferably 0.5 to 3% (m/m), so as to reduce or avoid skin irritation.

Multi-layered transdermal system with triazine UV absorber

Transdermal delivery of hormones without the need of penetration enhancers

The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.

UV stable transdermal therapeutic plaster with a UV absorbing adhesive layer separated from the drug matrix

Growing community of inventors

Jena, Germany

Thomas Langguth